Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: A placebo-controlled study

American Journal of Cardiovascular Drugs

Volumn 11, Issue 5, 2011, Pages 327-333

  Drummond, W ^a   Sirenko, Y M ^b   Ramos, E ^c   Baek, I ^d   Keefe, D L ^d  

^a Renaissance Research and Hypertension of Texas   (United States)

^b Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^c UNIVERSITY OF SEVILLE   (Spain)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aliskiren; Diabetes mellitus; Hypertension; Valsartanhydrochlorothiazide

Indexed keywords

ALISKIREN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; PLACEBO; VALSARTAN;

ADD ON THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; CHOLELITHIASIS; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; INFLUENZA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SITTING; SYSTOLIC BLOOD PRESSURE; TENDON RUPTURE; UREA NITROGEN BLOOD LEVEL;

AGED; AMIDES; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PATIENT DROPOUTS; POTASSIUM; SINGLE-BLIND METHOD;

EID: 80052698519     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11591970-000000000-00000     Document Type: Article

References (35)

1. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-9 (Pubitemid 32304003)
2. El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep 2004; 6: 215-23 (Pubitemid 39359564)
3. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension 1995; 26: 869-79
4. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-246
5. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26: S80-2
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52 (Pubitemid 37553153)
7. Bakris GL, Sowers JR. ASH position paper: treatment of hypertension in patients with diabetes - an update. J Clin Hypertens (Greenwich) 2008; 10: 707-13; discussion 714-5
8. Messerli FH, Grossman E, Goldbourt U. Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens 2001; 14: 12S-6S (Pubitemid 32424147)
9. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of theHypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62 (Pubitemid 28269185)
10. Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 1998; 317: 703-13 (Pubitemid 28414300)
11. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment of cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92 (Pubitemid 26419185)
12. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21 (4): 597-603 (Pubitemid 28172941)
13. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9
14. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-46 (Pubitemid 351793017)
15. Hayashi T, Takai S, Yamashita C. Impact of the renin- angiotensinaldosterone- system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol 2010; 8 (2): 189-97
16. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
17. Mü ller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006; 1: 221-8
18. Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32 (10): 1873-9
19. Tekturna. US prescribing information. Novartis Pharmaceuticals Corporation, East Hanover (NJ), 2010
20. Rasilez. EU summary of product characteristics. Novartis Europharm Ltd, Horsham, 2010
21. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct rennin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-8 (Pubitemid 351166266)
22. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-85 (Pubitemid 38425770)
23. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119 (3): 371-3
24. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217-26 (Pubitemid 44885684)
25. Chrysant SG. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. Expert Rev Cardiovasc Ther 2008; 6: 305-14
26. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, doubleblind trial. Lancet 2007; 370: 221-9 (Pubitemid 47069535)
27. Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047-55 (Pubitemid 351664315)
28. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective rennin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20 (Pubitemid 46014059)
29. Townsend RR, Forker A, Rumpelt P, et al. Initial combination therapy with aliskiren/hydrochlorothiazide is more effective than amlodipine in patients with stage 2 systolic hypertension and diabetes mellitus [abstract no. LB-PO- 03]. J Clin Hypertens 2010; 12 (7): 534
30. Zieve F, Yadao A, Yurkovic C, et al. Aliskiren with or without hydrochlorothiazide lowers blood pressure effectively in patients with stage 2 hypertension andmetabolic syndrome [abstract no. PP.38505]. J Hypertens 2010; 28 eSuppl. A: e600
31. Whaley-Connell A, Sowers J, Purkayastha D, et al. Combination therapy with aliskiren and HCTZ decreases plasma renin activity and oxidative stress vs ramipril while reducing blood pressure in obese patients with stage 2 hypertension [abstract no. PO-66]. J Clin Hypertens 2010; 12 Suppl. 1: A46
32. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-45 (Pubitemid 351664214)
33. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1423-31
34. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24 (5): 1663-71
35. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-8 (Pubitemid 40354519)